关键词：多囊卵巢综合征；内分泌激素；不规则；无月经；不规则排卵
摘 要：PCOS, also known as Stein-Leventhal syndrome, is one of the most common hormonal endocrine disorders in women. It is characterized by polycystic ovaries, irregular or no menstrual periods, irregular ovulation, and high levels of androgens (male hormones) in the body. The exact cause of PCOS is unknown. In PCOS, small cysts form on the ovaries, which do not produce a sufficient amount of the hormone that initiates ovulation. The ovarian follicles, which are filled with fluid in preparation for ovulation, remain as cysts when ovulation does not occur. Lifestyle modifications, medications, and surgery are some of the treatments currently available for PCOS.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

Product Profiles

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Competitive Analysis of Marketed

Products

08. Pipeline Snapshot

09. Rate of Incidence and Prevalence

09.1.1 Americas

09.1.2 Europe

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

18.1 Competitive Scenario

18.1.1 Key News

18.1.2 Mergers and Acquisitions

18.2 Vendor Analysis 2013

18.3 Other Prominent Vendors

19. Key Vendor Analysis

19.1 Bristol-Myers Squibb Co.

19.1.1 Key Facts

19.1.2 Business Overview

19.1.3 Key Product Offerings

19.1.4 Revenue by Geography

19.1.5 Business Strategy

19.1.6 Key Information

19.1.7 SWOT Analysis

19.1.8 Strengths

19.1.9 Weaknesses

19.1.10 Opportunities

19.1.11 Threats

19.2 Merck & Co. Inc.

19.2.1 Key Facts

19.2.2 Business Description

19.2.3 Business Segmentation

19.2.4 Revenue by Business Segmentation

19.2.5 Revenue Comparison 2012 and 2013

19.2.6 Sales by Geography

19.2.7 Business Strategy

19.2.8 Key Developments

19.2.9 SWOT Analysis

19.2.10 Strengths

19.2.11 Weaknesses

19.2.12 Opportunities

19.2.13 Threats

19.3 Novartis AG 8

19.3.1 Key Facts

19.3.2 Business Description

19.3.3 Business Segmentation

19.3.4 Revenue by Business Segmentation

19.3.5 Revenue Comparison 2012 and 2013

19.3.6 Sales by Geography

19.3.7 Business Strategy

19.3.8 Key Developments

19.3.9 SWOT Analysis

19.3.10 Strengths

19.3.11 Weaknesses

19.3.12 Opportunities

19.3.13 Threats

19.4 Sanofi SA

19.4.1 Key Facts

19.4.2 Business Description

19.4.3 Business Segmentation

19.4.4 Revenue by Business Segmentation

19.4.5 Revenue Comparison 2012 and 2013

19.4.6 Sales by Geography

19.4.7 Business Strategy

19.4.8 Key Developments

19.4.9 SWOT Analysis

19.4.10 Strengths

19.4.11 Weaknesses

19.4.12 Opportunities

19.4.13 Threats

19.5 Teva Pharmaceutical Industries Ltd.

19.5.1 Key Facts

19.5.2 Business Overview

19.5.3 Business Segmentation

19.5.4 Revenue by Business Segmentation

19.5.5 Revenue Comparison 2012 and 2013

19.5.6 Revenue Segmentation by Geography

19.5.7 Business Strategy

19.5.8 Key Developments

19.5.9 SWOT Analysis

19.5.10 Strengths

19.5.11 Weaknesses

19.5.12 Opportunities

19.5.13 Threats

20. Other Reports in this Series